Novogene Co., Ltd. (SHA:688315)
China · Delayed Price · Currency is CNY 15.28
-0.36 (-2.30%)
At close: Feb 13, 2026
Novogene Market Cap
Novogene has a market cap or net worth of 6.19 billion as of February 13, 2026. Its market cap has increased by 30.04% in one year.
Market Cap
6.19B
Enterprise Value
4.75B
Revenue
2.17B
Ranking
n/a
PE Ratio
35.47
Stock Price
15.28
Market Cap Chart
Since April 13, 2021, Novogene's market cap has decreased from 10.97B to 6.19B, a decrease of -43.56%. That is a compound annual growth rate of -11.14%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 13, 2026 | 6.19B | 15.06% |
| Dec 31, 2025 | 5.38B | 6.24% |
| Dec 31, 2024 | 5.06B | -47.88% |
| Dec 29, 2023 | 9.71B | -8.02% |
| Dec 30, 2022 | 10.56B | -36.10% |
| Dec 31, 2021 | 16.53B | 50.73% |
| Apr 13, 2021 | 10.97B | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GemPharmatech | 7.15B |
| Jiangsu Aidea Pharmaceutical Group | 7.07B |
| Shenzhen Weiguang Biological Products | 7.00B |
| Shanghai OPM Biosciences | 6.92B |
| Beijing Konruns Pharmaceutical | 6.72B |
| PharmaResources (Shanghai) | 6.35B |
| Xiangxue Pharmaceutical | 6.22B |
| Kexing Biopharm | 6.05B |